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INTRODUCTION
Immune-mediated hemolytic anemia (IMHA) is ra-
rely seen in cats, and in the majority of cases the di-
sease occurs secondary to an underlying infectious,
neoplastic or inflammatory condition (McCullough,
2003). The diagnosis of primary IMHA is made when
immune-mediated red blood cell (RBC) destruction is
present in the absence of an underlying cause (Kohn et
al., 2006). 
In more than half (58%) of cats with IMHA, non-
regenerative anemia is seen, which can be a conse-
quence of the acute onset of the disease, because 3 to
5 days are required to develop a substantial reticulocyte
response (Kohn et al., 2006; Weis, 2008). When signs
of regeneration are still absent 5 days after the onset of
the anemia, bone marrow should be examined to de-
termine whether the animal has erythroid maturation
arrest, which would suggest the immune-mediated de-
struction of erythroid precursors or erythroid hyper-
plasia. A higher mortality rate is seen in cats with non-
regenerative IMHA and bone marrow erythroid hy-
perplasia than in those with erythroid maturation arrest
or with pure red cell aplasia (Weis, 2008).
This case report describes a young male cat with
non-regenerative primary IMHA and bone marrow
erythroid maturation arrest with mild myelodysplasia.
CASE REPORT
A two-year-old male, castrated domestic shorthair
cat with a body weight of 3.8 kg was presented at the
Department of Small Animal Internal Medicine of the
Ghent University Faculty of Veterinary Medicine be-
cause of a 5-day history of lethargy and anorexia. One
week before presentation, the cat had an episode of
diarrhea which had resolved without treatment. Other-
wise, the cat had no medical history. The cat was kept
indoors, with limited outdoor access. It had regularly,
though not recently, been vaccinated against feline
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ABSTRACT
A two-year-old male domestic shorthair cat was referred to the Department of Small Animal Medicine and
Clinical Biology at the Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium because of
lethargy and anorexia. The cat had severe non-regenerative anemia and marked lymphocytosis. Primary non-
regenerative immune-mediated hemolytic anemia was diagnosed on the basis of severe hemolytic anemia in
combination with a positive osmotic fragility test, a positive Coombs test and the exclusion of underlying
causes. A bone marrow core biopsy revealed erythroid maturation arrest with mild myelodysplasia. The cat
responded quickly to treatment with a blood transfusion and immunosuppressive dosages of prednisolone. The
prednisolone was tapered down and stopped after 5 months. Two years after the initial diagnosis, there were
no signs of clinical relapse.  
SAMENVATTING
Een twee jaar oude kater werd doorverwezen naar de vakgroep Geneeskunde en Klinische Biologie van de Kleine
Huisdieren van de Faculteit Diergeneeskunde in Merelbeke, België omwille van lethargie en anorexia. De kat had
een uitgesproken niet-regeneratieve anemie en lymfocytose. De diagnose van niet-regeneratieve primaire
immuungemedieerde hemolytische anemie werd gesteld op basis van de aanwezigheid van hemolytische anemie in
combinatie met een positieve osmotische fragiliteitstest, een positieve coombstest en de uitsluiting van onderliggende
oorzaken. Het onderzoek van een beenmergbiopt wees op een maturatiestop van de rode bloedcellen en op milde
myelodysplasie. De kat reageerde zeer snel op de behandeling met een bloedtransfusie en prednisolone aan een
immunosuppressieve dosis. De prednisolone werd afgebouwd en stopgezet na 5 maanden. Twee jaar na het stellen
van de diagnose vertoonde de kat geen tekenen van klinisch recidief. 
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calicivirus, feline panleukopenia virus and feline her-
pes virus type I and was being fed a commercial feline
diet. 
The referring veterinarian had performed a com-
plete blood count one day earlier which showed severe,
non-regenerative anemia, severe lymphocytosis and
mild thrombocytopenia. The cat was referred to per-
form further tests.     
On physical examination, the cat was lethargic, had
severely pale mucous membranes, tachycardia (heart
rate of 212 beats/min) with strong femoral pulse qua-
lity, and a rectal temperature of 37.7°C. Other findings
were unremarkable. Pale mucous membranes can be a
result of shock or anemia. Tachycardia can be a result
of anemia, hypoxia, hypovolemia, hypotension, pain,
fever or stress. In this cat the severe anemia, detected
on CBC by the referring veterinarian, was assumed to
be the cause of the pale mucous membranes and the ta-
chycardia. A serum biochemistry profile and urine ana-
lysis were performed and the CBC was repeated to eva-
luate the packed cell volume (PCV) and to determine
whether the anemia had become regenerative or not.
The results of the CBC are presented in Table 1. On the
serum biochemistry profile, the only abnormality was
hyperbilirubinemia (total bilirubine 17.4 µmol/L {re-
ference range < 6.8 µmol/L}). On urine analysis, bili-
rubinuria was present. A commercially available
ELISA test (SNAPTM Combo Plus) was negative for
FIV antibodies and FeLV antigen.
On a blood smear (Figure 1), a sufficient number of
platelets (more than 10 platelets per oil immersion
field (100x)) was present. The erythrocytes showed
mild anisocytosis and mild polychromasia. Further-
more, a markedly increased number of reactive lym-
phocytes were seen.
The cat received oxygen and blood typing was per-
formed. A total of 60 mL fresh whole blood (type A
blood) was immediately transfused at a rate of 10
mL/kg/h. Furthermore, the cat was warmed with an in-
frared light. 
Considering the severe anemia with marked hyper-
bilirubinemia and the absence of other abnormalities on
blood and urine analysis, the cat was suspected of ha-
ving hemolytic anemia. The important differentials
for hemolysis in this cat were the immune-mediated
destruction of RBCs (primary or secondary), heredi-
tary erythrocyte membrane defects, infectious causes
(Mycoplasma M. hemofelis, Babesia felis) and intoxi-
cation (lead, acetaminophen or methylene blue). Addi-
tional laboratory tests to detect the cause of hemolysis
were carried out. The autoagglutination test, performed
by mixing 5 drops of 0.9% NaCl with 1 drop of the pa-
tient’s blood on a smear slide, was negative. The RBC
osmotic fragility test was carried out by adding 5 drops
of blood to each of two tubes containing 5 mL of a
0.62% and a 0.9% NaCl solution, respectively. After
standing at room temperature for 5 minutes, the two tu-
bes were centrifuged at 3500 rpm for 5 minutes. The
osmotic fragility (OF) test was positive, because the su-
pernatant of the 0.62% NaCl solution was red, in con-
trast to the colorless supernatant of the 0.9% NaCl so-
lution (Figure 2). A Coombs test was performed by
Table 1. Results of complete blood count on the day of
submission.
Reference range
Hct (%) 7.1 24-45
MCV (fl) 39.8 37-55
MCH (pg) 14 12-18
MCHC (g/dL) 35.1 30-36
Leucocytes (/µL) 16710 5000-15000 
Band neutrophils (/µL) 0 < 550
Segmented neutrophils (/µL) 3175 3600-10500
Lymphocytes (/µL) 11363 900-4200
Monocytes (/µL) 1838 <550
Basophils (/µL) 0 0-80
Eosinophils (/µl) 334 <800
Platelets (/µL) 111900 175000-500000
Reticulocytes (%) 0.004 <0.013
Figure 1. Blood smear with a low cellularity. Further-
more, mild erythrocyte anisocytosis and polychromasia
and an increased number of lymphocytes can be seen
(HE, 60x). 
Figure 2. A positive osmotic fragility test with a red su-
pernatant (due to hemolysis) in 0.62% NaCl and with a
colorless supernatant in 0.9% NaCl.
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using two 96 well HTS microplates containing anti-fe-
line globulin IgG and IgM in the gel matrix, one at 37°
and one at 4 °C The coombs’ test was positive at 37°C. 
Immune-mediated hemolytic anemia (IMHA) was
diagnosed on the basis of the combination of severe
hemolytic anemia, the positive OF test and the positive
Coombs test.
After the transfusion, the PCV increased to 12.5%
and the clinical status of the cat improved, which made
it possible to perform additional diagnostic tests to de-
tect the possible underlying cause of the IMHA. Tho-
racic radiography and abdominal ultrasonography re-
vealed no abnormalities. Because the anemia was
non-regenerative and clinical symptoms had already
been present for up to 5 days (erythrocyte regeneration
is expected after 3 to 5 days), a bone marrow core
biopsy was taken and cytology and histopathology
were performed. The cat was anesthetized using me-
thadone (0.1 mg/kg) as premedication and propofol (6
mg/kg) as induction and maintenance. The bone mar-
row was aspirated with an 18G needle (Spinocan®).
Bone marrow cytology and histopathology revealed
moderate hypercellularity and a moderate amount of
small lymphocytes with normal morphologic featu-
res. Scattered megakaryocytes were found. Erythroid
series cells were present at all stages of maturation into
the metarubricyte stage, and myeloid series cells were
observed mostly at the early blast and promyelocyte
stages, suggesting a maturation arrest in both cell lines
(Figures 3 and 4). Furthermore, a mild myelodysplasia
was considered to be present, based upon the presence
of megaloblasts. An aliquot of the bone marrow was
used to perform PCR assays for FeLV, Mycoplasma
hemofelis, Candidatus mycoplasma hemominutum and
Candidatus mycoplasma turicensis. All PCR assays
were performed in the ‘Laboratoire d’analyses vétéri-
naires’, Scanelis, France and were negative. 
By exclusion of other causes, a primary non-rege-
nerative IMHA was suspected in this cat and treatment
with immunosuppressive dosages of corticosteroids
(prednisolone, 1 mg/kg twice daily) was started. Ad-
ditional therapy included infusion of crystalloids (NaCl
0.9% solution, 50 mL/kg/24h) and prophylactic IV ad-
ministration of a histamine blocker (ranitidine, 2 mg/kg
twice daily). The PCV continued to improve and re-
turned to reference ranges 13 days after the initial
diagnosis. The PCV was checked two weeks thereafter
and was still within reference ranges. At that time, the
dosage of prednisolone was decreased to 0.75 mg/kg
twice daily. Subsequently, a blood sample for hemato-
logy was taken monthly and the dosage of prednisolone
was tapered down by25% each month. The lymphocyte
counts remained high and were still slightly above re-
ference ranges (4500/µL {reference range 900 to
4200/µL}) when a last blood sample was taken, 5
months after the initial diagnosis. At that moment, the
PCV was 42% and the cat was doing well clinically,
while receiving prednisolone at 0.5 mg/kg once daily,
every other day. Therapy with prednisolone was stop-
ped. Two years after diagnosis, the cat was still clini-
cally healthy. 
DISCUSSION
In the reported case, the diagnosis of primary non-
regenerative IMHA was based upon the evidence of
hemolysis, the evidence of immune-mediated RBC de-
struction (positive Coombs’ test and positive OF test),
the exclusion of underlying causes and its good res-
ponse to immunosuppressive corticosteroid treatment.
Only when, despite extensive investigation, no un-
derlying cause for the immune-mediated destruction of
the RBC’s can be identified, is a diagnosis of primary
IMHAmade. However, in patients with primary IMHA
the possibility cannot be completely excluded that
there might have been a trigger to the immune-media-
ted RBC destruction, as the trigger might have dis -
appeared already.
The autoagglutination test was negative, sugges ting
that the IMHA in this case was probably caused by the
Figure 4. Cytology of a bone marrow aspirate showing pre-
dominantly erythroid series cells at different stages of ma-
turation into the metarubricyte stage and few myeloid series
cells at the early blast and promyelocyte stages (HE, 100x). 
Figure 3. Cytology of a bone marrow aspirate showing
erythroid series cells at all stages of maturation into the
metarubricyte stage and a moderate amount of small ma-
ture lymphocytes (HE, 60x). 
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presence of warm-type IgG antibodies, which may
dissolve after the addition of NaCl solution (Slappen-
del, 1986).
While in the majority of dogs IMHA is primary, this
condition is only rarely seen in cats (McCullough,
2003). In contrast to IMHA dogs, which are most of-
ten presented with a regenerative anemia, the majority
of cats have a non-regenerative anemia, which was also
seen in this case (Reimer et al., 1999; Kohn et al.,
2006). On bone marrow cytology and histopathology
an erythroid maturation arrest and mild myelodyspla-
sia were present. Furthermore, a moderate lymphocyte
hyperplasia was seen, which has been reported to be
present in the bone marrow of 86% of cats with IMHA
(Weiss, 2008). Erythroid maturation arrest may result
from immune-mediated destruction of erythroid pre-
cursor cells within the bone marrow (Weiss, 1986).
Myelodysplasia has been associated with the produc-
tion of defective RBCs that have a higher rate of ap-
optosis (Weiss and Aird, 2001). Therefore, the non-re-
generative character of the anemia in this cat was likely
a consequence both of the immune-mediated destruc-
tion of RBC precursors and ineffective erythropoiesis. 
The clinical presentation of the cat in this report is
in agreement with what has been reported in the lite-
rature (Kohn, 2006). The cat was presented with non-
specific symptoms of anorexia and lethargy, and phy-
sical examination revealed abnormalities such as pale
mucous membranes, tachycardia and strong femoral
pulses, all of which are consequences of severe anemia. 
The laboratory abnormalities (severe anemia, mild
thrombocytopenia, marked lymphocytosis, hyperbili-
rubinemia) seen in this cat have all been reported in
cats with IMHA. The mild thrombocytopenia in this cat
was due to a ‘pseudothrombocytopenia’. Feline plate-
let concentrations are often falsely decreased because
of platelet clumping when automated hematologyana-
lyzers are used. Furthermore, automated cell counters
that have a threshold function to separate platelets and
RBCs by volume are often inaccurate when used with
cats, because a considerable overlap exists between
platelet and RBC volumes in this species. Because of
this, counting the number of platelets on a blood smear
is always necessary for cats in which the automated
platelet count is low. Ten to 20 platelets per oil im-
mersion field (100x) are considered adequate (Callan,
2010). A marked lymphocytosis was seen in the cat of
this report and has been reported to be present on the
CBC of 32% of cats with primary IMHA (McManus et
al., 2001; Kohn et al., 2006). It is remarkable that the
lymphocyte counts remained high even after 5 months
of treatment, while the PCV was within reference ran-
ges. Husbands et al. (2002) reported a lymphocytosis
that persisted in 2 of the 25 cats with primary IMHA,
and that recurred with a relapse of anemia despite
prednisolone therapy in 3 of the 25 cats. It is unclear
why the lymphocyte counts remained persistently high
in these cases. A possible explanation is chronic anti-
genic stimulation despite corticosteroid treatment. 
The cat in this report only required one blood
transfusion. Although the PCV after blood transfusion
was only 12.5%, the clinical signs of anemia, such as
tachycardia and tachypnea, had resolved. Further-
more, the cat was bright and alert and it was consi dered
safe to anesthetize the cat to perform a bone marrow as-
piration. A combination of opioids (premedi cation) and
propofol (induction and maintenance), was chosen be-
cause of the minimal cardiovascular side effects of
these drugs. In the present case, PCR for hemotropic
mycoplasma species was performed on bone marrow.
In cases where bone marrow is not aspirated, the PCR
assay can be performed on whole uncentrifuged blood
on EDTA.
The cat in this report responded quickly to treatment
with a rather low dosage of prednisolone. In the study
of Kohn et al. (2006), the majority of cats (85%) re-
quired more than 14 days before the PCV returned to
normal, while in this cat PCV was within reference ran-
ges after 13 days of treatment.
As described in the literature, the dosage of pred-
nisolone was slowly tapered down over a 5-month pe-
riod. Two years after the initial diagnosis the cat was
still clinically healthy. 
CONCLUSION
In this report a case of a young male cat with non-
regenerative primary IMHA was presented. Examina-
tion of the bone marrow revealed erythroid maturation
arrest with mild myelodysplasia, which led to the con-
clusion that the non-regenerative anemia in this cat was
probably a consequence both of the immune-mediated
destruction of RBC precursors and of ineffective
erythropoiesis. 
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